Platelet ADP receptor inhibitors

US8524721B2 · kind B2 · utility

Assignee

• Portola Pharmaceuticals, Inc. · US

Inventors

• Robert M. Scarborough · Belmont, US
• Hans-Michael Jantzen · San Francisco, US
• Wolin Huang · Foster City, US
• David M. Sedlock · Burlingame, US
• Charles K. Marlowe · Belmont, US
• Kim Kane-Maguire · Belmont, US

Key dates

• Filing date: Oct 10, 2011
• Grant date: Sep 3, 2013
• Expiry date: Oct 10, 2031

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D521/00
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

Novel compounds of formulae (I) and (VIII), which more particularly include sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives which are effective platelet ADP receptor inhibitors. These derivatives may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of cardiovascular diseases, particularly those diseases related to thrombosis. The invention also relates to a method for preventing or treating thrombosis in a mammal comprising the step of administering a therapeutically effective amount of a compound of formulae (I) to (VIII), or a pharmaceutically acceptable salt thereof.